On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
The FDA on Friday approved acellular tissue engineered vessel (Symvess), an off-the-shelf product for treating vascular trauma in the extremities of adults. The one-time, single-use therapy -- the ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
Are you a houseplant lover? Can’t get enough green, leafy plants? We have some exciting news for you. A French startup called Neoplants recently launched a bioengineered houseplant designed to clean ...
The Mayo Foundation for Medical Education and Research, the nonprofit parent entity of the Mayo Clinic, is a worldwide research powerhouse that is assigned scores of U.S. patents each year. Mayo ...
A new type of bioengineered blood vessel showed strong results in treating severe vascular injuries, potentially offering vascular surgeons a better alternative to synthetic grafts when patients' ...
The Ninth Circuit Court of Appeals on Friday found the Agriculture Department unlawfully excluded highly refined foods from ...
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into ...
The Grande Ronde Hospital (GRH) Wound Clinic, located at 700 Sunset Dr., Suite F, has experienced significant growth over the past 15 years, evolving from a single-room clinic in the SurgiCenter that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback